AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34319865 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 34320161 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving 60% of energy delivery targets within 7 days
Number of subjects: 1844
Study 34320161 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving 60% of protein delivery targets within 7 days
Number of subjects: 1844
Study 34320161 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving targets within the first 7 days
Number of subjects: 1844
Study 34320207 — intervention group
Group type: EXPERIMENTAL
Intervention: Burgers, Fries, & Soft Drinks dietary pattern
Number of subjects: 14099
Study 34320207 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish dietary pattern
Number of subjects: 14099
Study 34320207 — intervention group
Group type: EXPERIMENTAL
Intervention: White Rice, Beans, & Red Meats dietary pattern
Number of subjects: 14099
Study 34320207 — intervention group
Group type: EXPERIMENTAL
Intervention: Years living in the United States
Number of subjects: 14099
Study 34320287 — intervention group
Group type: EXPERIMENTAL
Intervention: Risdiplam
Number of subjects: 41
Study 34320286 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, metformin plus rosiglitazone, or metformin plus intensive lifestyle intervention during the initial trial; transitioned to metformin with or without insulin during follow-up.
Number of subjects: 500
Study 34320342 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological inhibition of p38 MAPK or PRMT1
Number of subjects: 0
Study 34320342 — intervention group
Group type: COMPARATOR
Intervention: High levels of p38 MAPK and PRMT1
Number of subjects: 0
Study 34320504 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA) treatment
Number of subjects: 2282
Study 34320557 — intervention group
Group type: EXPERIMENTAL
Intervention: High exercise volume group (≥150 min/wk)
Number of subjects: 38
Study 34320785 — intervention group
Group type: EXPERIMENTAL
Intervention: Temsirolimus (TEM) 25 mg weekly and Lenalidomide (LEN) 20 mg on days 1-21 every 28 days
Number of subjects: 111
Study 34320839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 0
Study 34320839 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transvenous mitral commissurotomy (PTMC)
Number of subjects: 186
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate post-PTMC mitral valve area (IMVA) ≥ 2 cm
Number of subjects: 186
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing secondary antibiotic prophylaxis
Number of subjects: 186
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation rhythm
Number of subjects: 186
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilkins echocardiographic score > 8
Number of subjects: 186
Study 34320949 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-procedural systolic pulmonary arterial pressure
Number of subjects: 186
Study 34320980 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic glucocorticoid treatment (specific dosage and duration not mentioned)
Number of subjects: 0
Study 34320980 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 34321095 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month home-based physical training and respiratory rehabilitation program
Number of subjects: 39
Study 34321095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 39
Study 34321280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib (600-1000 mg daily) and Sirolimus (2-6 mg daily)
Number of subjects: 24
Study 34321280 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib and Sirolimus combination therapy
Number of subjects: 24
Study 34321407 — intervention group
Group type: EXPERIMENTAL
Intervention: Corvis Biomechanical Index (CBI) beta
Number of subjects: 448
Study 34321583 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib administered for > 3 weeks
Number of subjects: 613
Study 34321836 — intervention group
Group type: EXPERIMENTAL
Intervention: HLX01 (a rituximab biosimilar)
Number of subjects: 99
Study 34321836 — intervention group
Group type: COMPARATOR
Intervention: rituximab-CN (reference rituximab)
Number of subjects: 99
Study 34321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with gambling disorder (GbD)
Number of subjects: 120
Study 34321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with gaming disorder (GmD)
Number of subjects: 120
Study 34321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with sexual addiction (SA)
Number of subjects: 120
Study 34321880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive tasks for individuals with food addiction (FA)
Number of subjects: 120
Study 34321880 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 34321921 — intervention group
Group type: EXPERIMENTAL
Intervention: MPS-HA2% (single injection)
Number of subjects: 101
Study 34321944 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-individualized traditional acupuncture (TA)
Number of subjects: 140
Study 34321944 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive sham acupuncture (SA)
Number of subjects: 140
Study 34322077 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic Priming of Bilateral Approach
Number of subjects: 0
Study 34322089 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment style and social support interventions, details not available
Number of subjects: 0
Study 34322164 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprachoroidal injection of triamcinolone acetonide suspension (CLS-TA)
Number of subjects: 0
Study 34322164 — intervention group
Group type: COMPARATOR
Intervention: Systemic or locally administered corticosteroids
Number of subjects: 0
Study 34322460 — intervention group
Group type: EXPERIMENTAL
Intervention: SafeBoosC-III Consortium intervention
Number of subjects: 0
Study 34322463 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic lung area measurement
Number of subjects: 77
Study 34322463 — intervention group
Group type: EXPERIMENTAL
Intervention: sPAP measurement
Number of subjects: 77
Study 34322775 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib (45 mg and 30 mg intravenously on days 1, 8, and 15 of 28-day cycles) in combination with cetuximab (standard doses of 400 mg/m weekly)
Number of subjects: 0
Study 34322918 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular ICD (EV ICD) system
Number of subjects: 400
Study 34323296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients with sarcopenia
Number of subjects: 36
Study 34323296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients without sarcopenia
Number of subjects: 36
Study 34323296 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CS) patients
Number of subjects: 36
Study 34323296 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 36
Study 34323406 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy
Number of subjects: 29
Study 34323413 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of collagenase Clostridium histolyticum (CCH) at high doses (0.1-0.2 mg/cm)
Number of subjects: 0
Study 34323413 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin and nintedanib (FDA-approved drugs)
Number of subjects: 0
Study 34323526 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted education program; median time of 91 min to complete.
Number of subjects: 0
Study 34323541 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived discrimination (PD)
Number of subjects: 169
Study 34323541 — intervention group
Group type: EXPERIMENTAL
Intervention: Just-in-time adaptive interventions (JITAIs)
Number of subjects: 169
Study 34323851 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemic-Pandemic Impacts Inventory (EPII) survey
Number of subjects: 245
Study 34323955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP) at standard doses (900 mg/week)
Number of subjects: 50
Study 34323955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP) in pregnant women with HIV
Number of subjects: 50
Study 34323955 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly isoniazid and rifapentine (3HP)
Number of subjects: 50
Study 34323957 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Number of subjects: 2620
Study 34323957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 2620
Study 34323958 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 34323958 — intervention group
Group type: COMPARATOR
Intervention: G-CHOP (Obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 34324028 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 300 mg single dose
Number of subjects: 17
Study 34324028 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg daily (MHI)
Number of subjects: 17
Study 34324028 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib 200 mg or 300 mg based on weight and platelets (NHF)
Number of subjects: 17
Study 34324046 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified formula feeding with MFGM components
Number of subjects: 44
Study 34324046 — intervention group
Group type: COMPARATOR
Intervention: Breast milk feeding
Number of subjects: 44
Study 34324046 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro growth experiment with MFGM components (lactadherin, sialic acid, phospholipid)
Number of subjects: 44
Study 34324166 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectralis SD-OCT
Number of subjects: 272
Study 34324166 — intervention group
Group type: EXPERIMENTAL
Intervention: Optovue SD-OCT
Number of subjects: 272
Study 34324166 — intervention group
Group type: EXPERIMENTAL
Intervention: All three OCT instruments
Number of subjects: 272
Study 34324392 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD7 CAR T cells, single infusion at a dose of 5 × 10
Number of subjects: 20
Study 34324441 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2)
Number of subjects: 0
Study 34324451 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiated in the first week of life
Number of subjects: 257
Study 34324451 — intervention group
Group type: EXPERIMENTAL
Intervention: Defective sequences
Number of subjects: 257
Study 34324451 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact sequences
Number of subjects: 257
Study 34324500 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 0
Study 34324500 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional status children
Number of subjects: 0
Study 34324524 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 0
Study 34324524 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients
Number of subjects: 0
Study 34324628 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions to improve recruitment (e.g., increasing recruitment sites, providing extra time, communication training for study staff, redesigning patient information)
Number of subjects: 7612
Study 34324628 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures to improve retention (e.g., maintaining close contact with participants, showing appreciation, reimbursing travel arrangements)
Number of subjects: 7612
Study 34324909 — intervention group
Group type: COMPARATOR
Intervention: Baseline Go/Nogo (non-reward incentivized/control)
Number of subjects: 66
Study 34324909 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward incentivized Go/Nogo (food, money)
Number of subjects: 66
Study 34324909 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating in the absence of hunger (EAH)
Number of subjects: 66
Study 34324909 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward trials (food vs. money)
Number of subjects: 66
Study 34325107 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant or conversion chemotherapy
Number of subjects: 52
Study 34325453 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (improving restful sleep, exercise, eating at regulated mealtimes, avoiding dietary triggers) for at least 60 days
Number of subjects: 28
Study 34325523 — intervention group
Group type: EXPERIMENTAL
Intervention: Home discharge
Number of subjects: 3460
Study 34325523 — intervention group
Group type: COMPARATOR
Intervention: Nonhome discharge
Number of subjects: 3460
Study 34325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based, peer-led and incentivised SRH intervention
Number of subjects: 230
Study 34325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention points cards (PPC) for incentivising service use
Number of subjects: 230
Study 34325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based spaces (hubs) for service delivery
Number of subjects: 230
Study 34325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and characteristics of service providers
Number of subjects: 230
Study 34325696 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement process with AYP
Number of subjects: 230
Study 34325710 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical exercises monitoring alone
Number of subjects: 122
Study 34325710 — intervention group
Group type: COMPARATOR
Intervention: Combined physical exercises monitoring with home-based cognitive training
Number of subjects: 122
Study 34325726 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells (anti-GPC3-7 × 19 CAR-T)
Number of subjects: 0
Study 34325726 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 × 19 CAR-T cells (anti-MSLN-7 × 19 CAR-T)
Number of subjects: 0
Study 34325726 — intervention group
Group type: COMPARATOR
Intervention: Conventional CAR-T cells
Number of subjects: 0
Study 34325853 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive AI Retinal Expert (CARE) system
Number of subjects: 207228
Study 34326007 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem cells (BMSCs)
Number of subjects: 10
Study 34326007 — intervention group
Group type: COMPARATOR
Intervention: Phosphodiesterase type 5 inhibitors (PDE5Is)
Number of subjects: 10
Study 34326100 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF) defined as an estimated glomerular filtration rate (eGFR) decline greater than 40% from baseline.
Number of subjects: 10251
Study 34326100 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-high cardiovascular risk group
Number of subjects: 10251
Study 34326100 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening kidney function (WKF) event
Number of subjects: 10251
Study 34326179 — intervention group
Group type: EXPERIMENTAL
Intervention: First 1000 Days program
Number of subjects: 995
Study 34326179 — intervention group
Group type: COMPARATOR
Intervention: Usual care (comparison centers)
Number of subjects: 995
Study 34326187 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 34326188 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab (anti-IgE) treatment
Number of subjects: 405
Study 34326188 — intervention group
Group type: EXPERIMENTAL
Intervention: C4Ma3 degradation marker
Number of subjects: 405
Study 34326188 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulacimstat (chymase inhibitor)
Number of subjects: 405
Study 34326188 — intervention group
Group type: EXPERIMENTAL
Intervention: C4Ma3 levels
Number of subjects: 405
Study 34326800 — intervention group
Group type: EXPERIMENTAL
Intervention: Promoting Alternative Thinking Strategies (PATHS)
Number of subjects: 0
Study 34326800 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34326839 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoantigen reactive T cells combined with tomotherapy
Number of subjects: 1
Study 34326905 — intervention group
Group type: EXPERIMENTAL
Intervention: OCTA (Optical Coherence Tomography Angiography)
Number of subjects: 40
Study 34326905 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 40
Study 34326920 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month walking intervention with activity tracker
Number of subjects: 49
Study 34327136 — intervention group
Group type: EXPERIMENTAL
Intervention: Penpulimab (200 mg i.v. Q3W) plus Anlotinib (8 mg/day, 2 weeks on/1 week off)
Number of subjects: 31
Study 34327207 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (MV)
Number of subjects: 0
Study 34327207 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 0
Study 34327207 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) 25 mg bid as monotherapy or to background therapy
Number of subjects: 1759
Study 34327344 — intervention group
Group type: EXPERIMENTAL
Intervention: Iguratimod (IGU) 25 mg bid
Number of subjects: 1759
Study 34327406 — intervention group
Group type: EXPERIMENTAL
Intervention: Detachable string magnetically controlled capsule endoscopy (DS-MCCE)
Number of subjects: 105
Study 34327406 — intervention group
Group type: COMPARATOR
Intervention: Esophagogastroduodenoscopy (EGD)
Number of subjects: 105
Study 34327411 — intervention group
Group type: EXPERIMENTAL
Intervention: Sphincter preservation surgery
Number of subjects: 342
Study 34327411 — intervention group
Group type: COMPARATOR
Intervention: Abdominoperineal resection
Number of subjects: 342
Study 34327510 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonablative, Noncoagulative Multipolar Radiofrequency and Pulsed Electromagnetic Field Treatment
Number of subjects: 0
Study 34327561 — intervention group
Group type: EXPERIMENTAL
Intervention: dd-ABVD (dose-dense ABVD)
Number of subjects: 96
Study 34327604 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Aronia melanocarpa extract (SAE) 30 ml/day for 30 days
Number of subjects: 30
Study 34327735 — intervention group
Group type: EXPERIMENTAL
Intervention: LWYY model
Number of subjects: 8399
Study 34327735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox model
Number of subjects: 8399
Study 34327735 — intervention group
Group type: EXPERIMENTAL
Intervention: Mao-Lin model
Number of subjects: 8399
Study 34327735 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent event models
Number of subjects: 8399
Study 34327883 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight group (<18.5 kg/m²)
Number of subjects: 2914
Study 34327883 — intervention group
Group type: COMPARATOR
Intervention: Normal weight group (18.5-25 kg/m²)
Number of subjects: 2914
Study 34327883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight group (25-30 kg/m²)
Number of subjects: 2914
Study 34327883 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (≥30 kg/m²)
Number of subjects: 2914
Study 34328338 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel method for determining HER2 expression
Number of subjects: 0
Study 34328394 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic medical and psychiatric conditions (cluster 1: heart condition, hypertension, liver problems; cluster 2: gastrointestinal problems, head injury; cluster 3: anxiety disorder, bipolar disorder, schizophrenia)
Number of subjects: 1646
Study 34328394 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar disorder, liver problems, and individuals with one chronic condition
Number of subjects: 1646
Study 34328394 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart condition, hypertension, and GI problems
Number of subjects: 1646
Study 34328394 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorder, head injury, individuals with one or more than two psychiatric conditions, and individuals with more than two chronic conditions
Number of subjects: 1646
Study 34328428 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus mindfulness training
Number of subjects: 80
Study 34328428 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation, mindfulness training, and additional modules targeting maladaptive behavioral avoidance
Number of subjects: 80
Study 34328428 — intervention group
Group type: COMPARATOR
Intervention: Control group (Psychoeducation plus mindfulness training)
Number of subjects: 80
Study 34328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Step program (self-managed digital fall prevention exercise program)
Number of subjects: 25
Study 34328438 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe Step program
Number of subjects: 25
Study 34328563 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabellar tap sign (GR) in patients with Parkinson's disease (PD)
Number of subjects: 161
Study 34328563 — intervention group
Group type: EXPERIMENTAL
Intervention: Glabellar tap sign (GR) in patients with essential tremor (ET)
Number of subjects: 161
Study 34328563 — intervention group
Group type: COMPARATOR
Intervention: Glabellar tap sign (GR) in healthy controls
Number of subjects: 161
Study 34329317 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model based on 6 independent predictors of mortality (age, respiratory rate ≥25/minute, oxygenation <94%, hypertension, coronary artery disease, chronic renal disease)
Number of subjects: 3123
Study 34329317 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 3123
Study 34329317 — intervention group
Group type: EXPERIMENTAL
Intervention: Online calculator of 40-day COVID-19 mortality risk score
Number of subjects: 3123
Study 34329401 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with paroxysmal AF
Number of subjects: 364
Study 34329401 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with paroxysmal AF
Number of subjects: 364
Study 34329436 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective health measures (general health, role physical function, physical function)
Number of subjects: 2783
Study 34329436 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying effects modeling (TVEM)
Number of subjects: 2783